I’ve recently highlighted NVO (Novo Nordisk A/S) as an objective long entry following the 70% plunge to the dual intersecting long-term price & trendline support levels. With Novo’s biggest competitor’s (LLY- Eli Lilly & Co) earnings now out of the way, I wanted to pass along LLY as either a…